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Bladder cancer is the fifth most common cancer in males. Over
95% of all bladder cancers in industrialized countries are transi-
tional cell carcinomas (TCCs). TCCs are presented in two ways:
superficial papillary tumours, confined to the mucosa and lamina
propria; and invasive tumours spreading beyond the lamina
propria into detrusor muscle. The remaining 5% of tumours
include squamous cell carcinomas, adenocarcinomas and carci-
noma in situ.
Frequent somatic allelic loss is regarded as a hallmark of
tumour suppressor gene (TSG) inactivation. In TCCs, cytogenetic
studies and loss of heterozygosity (LOH) analyses have revealed a
number of chromosomal aberrations, including deletion of chro-
mosome 9p and/or 9q (Devlin et al, 1994) (Keen and Knowles,
1994) (Cairns et al, 1993; Linnenbach et al, 1993; Orlow et al,
1994), and deletions of chromosome 11p (Shipman et al, 1993),
18q (Brewster et al, 1994), chromosome 8 (Knowles et al, 1993;
Takle and Knowles, 1996), 4p (Elder et al, 1994; Polascik et al,
1995) and 14q (Chang, 1995). LOH of markers on chromosome 9
is found in TCCs of all grades and stages, suggesting that the inac-
tivation of a putative TSG on this chromosome is an early event in
the development of bladder cancer. Several groups (Ruppert et al,
1993; Habuchi et al, 1995; Simoneau et al, 1996) reported
evidence for the presence of more than one TSG that can
contribute to the development of bladder cancer on chromosome 9.
The CDKN2A (p16, MTS1) and CDKN2B (p15) genes are local-
ized on the short arm of chromosome 9. Recent studies showed the
inactivation of these genes in as much as 40–50% of bladder
tumours (Cairns, 1995; Akao et al, 1997). More detailed deletion
mapping on the long arm revealed two regions of loss (Habuchi et
al, 1995; Simoneau et al, 1996). Small interstitial deletions
covering the location of the marker D9S195 were recently
reported in five TCCs. The shortest region of overlap of these
deletions is estimated to amount to about 840 kb. The putative
TSG in this deleted in bladder cancer region (DBC1) was called
DBCCR1 (Habuchi et al, 1998). This DBC1 region does not
overlap with the two other regions described by Habuchi et al
(1995) and Simoneau et al (1996). Thus, the combined data
provide evidence for three TSGs on chromosome 9q that may play
a role in the pathogenesis of bladder cancer.
In the present study we used a polymerase chain reaction
(PCR)-based microsatellite assay to further delineate the extent of
the deletions at chromosome 9q. A combination of our data with
those of others, supports the view that apart from the DBC1 region
two other putative TSG loci may exist on chromosome 9q. These
two regions were called TCC1 and TCC2. We screened 17 bladder
tumour cell lines for homozygous deletions in these areas. No
evidence for homozygous deletions was obtained.
MATERIALS AND METHODS
DNA preparation
Matched pairs of 59 paraffin-embedded bladder tumours and
normal control tissue of the same patient were selected. Paraffin
sections were examined microscopically by a pathologist (Th v/d
K). Parts that represented tumour tissue were punched out of the
original paraffin blocks and newly embedded. DNA was isolated
by proteinase K (2 mg ml21) digestion of deparaffinized 5-mm
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University, PO Box 1738, 3000 DR Rotterdam, The Netherlandssections, followed by phenol–chloroform extraction and ethanol
precipitation. A haematoxylin and eosin stain of sections flanking
the sections used for DNA isolation was again controlled by the
pathologist. In general, the percentage tumour tissue in the mate-
rial dissected by this procedure was estimated to be over 90%.
The following bladder tumour cell lines were used: 253J, 575A,
647V, 1207, 5637, J82, Jon, RT4, RT112, SCaBER, SD, SW780,
SW800, SW1710, T24, VMCubI and VMCubII. Dr D Chopin,
Paris, kindly provided the cell lines 1207 and 647V. Genomic
DNA was prepared according to standard procedures (Sambrook
et al, 1989).
LOH analysis
For LOH analysis, microsatellite primer sequences were obtained
from the Genome DataBase (http://gdbwww.gdb.org/gdb). Thirty
primer pairs were used. On the short arm, the markers D9S178,
D9S171, D9S168, D9S165 and D9S156 were included. On the long
arm, the markers D9S153, D9S154, D9S158, D9S164, D9S166,
D9S173, D9S176, D9S177, D9S179, D9S180, D9S195, D9S196,
D9S197, D9S257, D9S264, D9S272, D9S275, D9S278, D9S280,
D9S283, D9S287, D9S1783, D9S1818, D9S1826 and D9S1838
were used. Template DNA (50 ng) was amplified in a total volume
of 15 ml reaction mixture containing 2.5 mM dNTPs, 10 pmol of the
appropriate primer combination and 0.25 units of Taq polymerase
(Supertaq). Products were labelled with a-32P-dATP.
Thermal cycling consisted of initial denaturation at 958C for
5 min, followed by 32 cycles of each 558C for 45 s, 728C for 40 s
and 948C for 40 s. The final elongation step was 728C for 10 min.
PCR products were separated on 6% denaturing polyacrylamide
gels. Detection was done by autoradiography and, when necessary,
followed by quantification using a Phosphorimager (Molecular
Dynamics, Sunnyvale, CA, USA). An allele was considered to be
lost when the intensity of the remaining signal was less than 50%
compared to the signal of the same allele in the matching control
DNA of the same patient.
Homozygous deletion screening
For the homozygous deletion mapping, 98 primer sequences were
obtained from the Whitehead Institute (http://www-genome.
wi.mit.edu/), the Sanger Centre (http://www.sanger.ac.uk) and The
Institute of Genome Research (TIGR) (http://www.tigr.org). All
primer sequences were from sequence tagged sites (STS) or
expressed sequence tags (EST) mapped between our TCC1 and
TCC2 border markers (http://www.ncbi.nlm.nih.gov/Science96).
Amplification was done as described for the LOH analysis, with
the exception of the presence of a second control primer set in the
reaction mixture. As a control, primers were used for the NF2
(exon 5 and 11; Jacoby et al, 1994) or MN1 genes on chromosome
22 (bp 5304–5421, forward: MN1–16, 5¢-AGG TTG GTA CCT
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Table 1 Percentages of allele signal left for bladder tumours tcc36 and
tcc39 as determined with the Phosphorimagera
Marker tcc36 tcc39
D9S165 0.94
D9S166 0.34
D9S264 0.15
D9S283 0.87 0.13
D9S197 0.51
D9S280 0.19
D9S287 0.57
D9S180 0.59 0.22
D9S272 NMc
D9S1783 NM
D9S176 0.77
D9S173 0.89
D9S177 1.14
D9S154 0.64
D9S275 0.73
D9S195 0.37
D9S179 0.38 0.76
D9S164 0.44
D9S1818 NIb
D9S1826 0.60
D9S158 0.86 0.60
D9S1838 0.65
aThe percentages were determined by comparing the intensity of the lost
allele in the tumour with the intensity of the same allele in normal control
DNA, in relation to the intensity of the other retained allele. bNI, not
informative; cNM, not measured.
Table 2 Overview of the ESTs and STSs used for HD mapping, ordered
from centromere to telomere
Located in TCC1 Located in TCC2
1 stSG8675 43 A002D08 84 U18543
2 WI-30336 44 A008R29 85 IB3089
3 A002Y36 45 IB543 86 WI-13592
4 WI-11585 46 WI-2958 87 WI-11542
5 CKS2 47 WI-6937 88 WI-6257
6 WI-11909 48 IR10 89 WI-12734
7 WI-16825 49 WI-13546 90 ROP
8 WI-12646 50 PTCH 91 WI-11957
9 stSG2370 51 WI-14826 92 FB23F1
10 stSG8105 52 WI-1941 93 WI-15097
11 WI-2414 53 WI-2013 94 WI-13608
12 stSG9248 54 stSG9221 95 NIB1929
13 WI-4860 55 WI-9350 96 WI-14271
14 A004T01 56 A006115 97 WI-11577
15 IB2336 57 WI-6378 98 WI-12991
16 IB3559 58 stSG8121
17 WI-9447 59 WI-9840
18 WI-2331 60 WI-9914
19 WI-6758 61 WI-9212
20 WI-17567 62 A003P31
21 WI-9905 63 WI-7974
22 A006N11 64 WI-7285
23 A006U15 65 WI-11414
24 NIB973 66 A001T44
25 stSG1471 67 WI-8684
26 stSG2118 68 TGFBR1
27 NIB722 69 A008N47
28 stSG2205 70 A005N10
29 stSG3724 71 WI-7447
30 WI-7541 72 WI-5249
31 WI-13139 73 WI-14669
32 A007K29 74 WI-7344
33 WI-6338 75 WI-3790
34 WI-6428 76 NIB1437
35 WI-4577 77 WI-15742
36 WI-532 78 WI-688
37 WI-8025 79 SGC31311
38 stSG1737 80 WI-11370
39 stSG2403 81 WI-2008
40 WI-15517 82 A008T08
41 A001U11 83 WI-4017
42 WI-2820GCT TAG TG, reverse: MN1–13, 5¢-GGG TTA ACA CTG GTA
ACA TAC), since there are no data suggesting the involvement of
either of these genes or the chromosome in bladder cancer. Since
the presence of a homozygous deletion in the CDKN2A gene was
known in eight of the 17 cell lines used, primers were included for
a 167 bp product spanning an intron–exon boundary of the
CDKN2A gene (Nobori et al, 1994). The detection of these dele-
tions was used as a positive control.
RESULTS
LOH analysis
Fifty-nine bladder tumours were screened for LOH of markers on
chromosome 9. Twenty-six tumours (44%) showed LOH for one
or more markers. No microsatellite instability was seen. Of these,
two tumours had a deletion confined to the p arm, in ten the loss
was confined to the q arm and in 12 cases both p and q arms were
affected. Losses on the short arm overlap the region containing the
CDKN2 locus, which is located telomeric to marker D9S171. Two
individual tumours were found to obtain different interstitial dele-
tions on chromosome 9q, suggesting two different TSG loci on this
chromosome arm. These are discussed in detail in the following
sections. Other regions of loss that were observed on 9q could
target both putative TSG loci on 9q and/or the CDKN2 locus and
did not contribute to a further delineation of these loci.
An interstitial deletion between D9S165 and D9S176
In tcc39 an interstitial deletion was observed between the flanking
markers D9S165 and D9S176. No loss was observed for three
microsatellite markers on 9p. Examples of the LOH analysis of 9q
are shown in Figure 1A. Between D9S165 and D9S176, a clear
LOH was observed for seven microsatellites. The autoradiogram
for one of these, D9S283, is shown in Figure 1A. The extent of
loss was also calculated with the Phosphorimager. The results
obtained are depicted in Table 1 in the lane marked tcc39. For
D9S283, the signal of the lost allele was measured to be 13% of
the control allele from normal tissue. For some of the other
markers, slightly higher values were observed. This is probably
due to the fact that when two alleles are relatively close together
and comprise several stutter bands, they contribute to each other’s
background. In some cases, i.e. for D9S272 and D9S1783, this
makes the quantitative analysis impossible, although with the eye
a clear LOH is evident. The region deleted in tcc39 is approxi-
mately 48 cM in size. Tcc39 was classified by the pathologist as
Ta/grade 2.
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Figure 1 Autoradiographs illustrating the LOH analyses for tcc36 and
tcc39. N: matched control DNA; T: tumour DNA. Arrows indicate deleted
alleles. (top) tcc39: markers D9S165 and D9S176 show retention, while
marker D9S283 shows loss of the lower allele. (bottom) tcc36: markers
D9S275 and D9S1826 show retention, while marker D9S195 shows a lower
intensity of the upper allele
39 1 SRO Marker
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Figure 2 The borders of the TCC1 region. Markers are shown in linkage
and physical mapping order according to the Whitehead Institute contig data
and CEPH/Généthon data. (l l) retention; (l) loss of heterozygosity; ( ) not
informative. On the right side, a vertical bar indicates the potential smallest
region of overlap, based on our results with tcc39 and the results of Habuchi
et al (1995)An interstitial deletion between D9S275 and D9S1826
Tcc36 is a T1/grade 2 bladder tumour in which 40% of the cells are
monosomic for chromosome 9 as determined by in situ hybridiza-
tion using the chromosome 9 heterochromatin region probe
pHUR98 (van Tilborg et al, 1998). Thus, tcc36 is heterogeneous
with respect to its genomic constitution. This partial loss of one
copy of chromosome 9 is also observed in the LOH analyses and is
reflected by the measured intensities of allele signals of around
60% as shown in Table 1. Three microsatellites show a remaining
signal of approximately 30–40% when compared to the control
DNA. This most likely reflects an interstitial deletion of 31 cM
flanked by markers D9S275 and D9S1826. Figure 1B shows repre-
sentative autoradiograms of the LOH analyses of tcc36. Based on
the signal intensities as measured by the Phosphorimager, the most
plausible model to explain these findings would be that one allele
of a putative TSG which is located within the interstitially deleted
area was first inactivated and that two individual second hits
targeting the other allele occurred in separate cells: (a) loss of an
entire copy of chromosome 9 as reflected by the subpopulation of
40% of the tumour cells that are monosomic for chromosome 9 and
(b) an interstitial deletion of the same copy of chromosome 9
present in approximately 25% of the tumour cells.
Homozygous deletion analysis
We next screened DNA from 17 bladder tumour cell lines for
homozygous deletions in these areas. For the more centromeric
region, 83 ESTs and STSs were selected between the markers
D9S153 and D9S176, a region of 27 cM. The borders of this region
are indicated in Figure 2, they were deduced based on our results
with tcc39 and the results of Habuchi et al (1995). The markers for
the homozygous deletion analysis are listed in Table 2. When the
markers are randomly distributed, this results in a density of one
marker per 300 kb. Special attention was paid to the prevention of
contaminating the PCR-reaction to avoid false positives, by strictly
separating the equipment used to handle amplified DNA from other
equipment. Separate work areas were used for pre- and post-ampli-
fication steps. Random negative controls were included. No
homozygous deletions were found. In addition, the region with an
interstitial deletion as defined by tcc36 was screened with 15 sets of
PCR primers, representing a density of 1 marker per 500 kb.
However, no evidence for homozygous deletions was obtained. As
a control we also screened the cell lines for deletions of the CDKN2
locus. Deletions were observed in eight of the 17 cell lines tested.
This confirms data obtained by others (Southgate et al, 1995;
Williamson et al, 1995; Tamimi et al, 1996).
DISCUSSION
The purpose of this study was to further define chromosome 9q
deletions in TCCs. Previous LOH analyses predicted that 57% of
tumours had deletions on chromosome 9p and 9q (Habuchi et al,
1995). The putative presence of two or more TSGs on the same
chromosome complicates the interpretation of the LOH analysis.
Most estimations for the losses of the whole chromosome are
based on allelotyping studies in which a limited number of 9p and
9q markers were used. This causes high percentages of apparent
complete loss of chromosome 9. It is our experience that when
more markers are used most of these apparent cases of monosomy
are in fact large terminal or interstitial deletions. This emphasizes
the importance of testing as many informative polymorphic
markers as possible. The CDKN2A (p16)/CDKN2B (p15) tumour
suppressor genes are located on the short arm of chromosome 9.
Loss of one or even both copies of these genes was shown to occur
in at least 40–50% of TCCs (Cairns, 1995; Akao et al, 1997). In
some cases, the region of LOH spreads from the CDKN2 region
beyond the centromere into the q arm of chromosome 9. Such a
deletion could target the CDKN2 region, a locus on the q arm or
even both. In addition, losses that are confined to the q arm of
chromosome 9 suggest the existence of more than one candidate
bladder gene on this arm. Also here it is often not possible to
define to which region the observed LOH contributes.
Our LOH results confirm the hypothesis that there are at least
two different putative tumour suppressor gene loci on the q arm.
The first, more centromeric region is called TCC1. The borders of
this new region, as depicted in Figure 2, are defined by the inter-
stitial deletion in tcc39 as reported in this work and an interstitial
deletion in a bladder tumour number 1 as published by Habuchi et
al (1995). For the definition of the region we have excluded
tumours in which LOH was observed based on only one tested
marker. Our results place the lower border of the TCC1 region at
marker D9S176, instead of D9S109. This reduces the size of the
region by 6 cM from 33 to 27 cM. In both our case tcc39 and case
1, the signal intensities of the remaining alleles are very low,
suggesting that the gene targeted by these deletions is inactivated
in most, if not all, tumour cells. Thus, inactivation of this gene may
represent an early event in the pathogenesis of these tumours.
For the definition of a second region, several possibilities exist.
These are shown in Figure 3. In this Figure the interstitial deletion
in tcc36 (this paper) is shown next to deletions as published by the
group of Knowles (Habuchi et al, 1995, 1997). The DBC1 region
was deducted from short interstitial deletions in five separate
tumours that have a shortest region of overlap of 840 kb in which
marker D9S195 is located (Habuchi et al, 1997). The first conclu-
sion from these combined data is that it is impossible to attribute
492 AAG van Tilborg et al
British Journal of Cancer (1999) 80(3/4), 489–494 © Cancer Research Campaign 1999
36 1 2 121 68 A B C Marker
D9S53
D9S58
D9S177
D9S59
HXB
D9S154
D9S103
D9S275
D9S1848
AFMA239ZE1
D9S195
D9S258
GSN
D9S61
D9S63
D9S179
ABL1
ASS
D9S1818
D9S164
D9S1826
D9S66
D9S67
D9S158
D9S1838
Figure 3 The borders of the DBC1 and TCC2 regions. Markers are shown
in linkage and physical mapping order according to the Whitehead Institute
contig data and CEPH/Généthon data. (l l) retention; (l) loss of
heterozygosity; ( ) not informative. On the right side, vertical bars indicate
the possible smallest regions of overlap, based on our results with tcc36 and
the results of Habuchi et al (1995, 1997) and Simoneau et al (1996). For an
explanation of the three possible SROs for TCC2 (A, B, and C), see textall deletions to one region. For instance, tumours 36 and 1 can both
target the DBC1 region, but case 2 clearly falls outside this region.
The three different possible SRO regions based on these data are
also shown in Figure 3. In Figure 3 lane A, it is assumed that both
tcc36 and case 1 target the DBC1 region. This would result in a
TCC2 region defined by case 2. In option B, tcc36 targets DBC1
and case 1 the TCC2 region, and reversely in option C, the case 2
deletion targets DBC1 and tcc36 TCC2. As a result, the size of the
TCC2 region can vary from 30 to 40 cM.
Approximately 40% of the cells in tcc36 are monosomic for
chromosome 9 and in an additional 25% an interstitial deletion of
the same copy of chromosome 9 occurred. This suggests that the
interstitial deletion and the loss of an entire chromosome may
target the same TSG and that for this gene these two events repre-
sent separate second hits. These findings suggest that the inactiva-
tion of the proposed TSG at this location may not have been one of
the first hits in the pathogenesis of tcc36.
Losses of chromosome 9q have also been observed in basal cell
carcinoma (Shanley et al, 1995), squamous cell carcinoma of the
head and neck (Ah-See et al, 1994), oesophagus carcinoma (Miura
et al, 1996), ovarian cancer (Shultz et al, 1995), renal cell carci-
noma (Cairns et al, 1995) and small-cell lung cancer (Merlo et al,
1994). Since the SROs for bladder cancer are still very large, with
the exception of the DBC1 region, it cannot be excluded that the
losses seen in other tumours target the same TSGs. Recently, the
gene responsible for sporadic basal cell carcinoma of the skin and
the hereditary disorder NBCCS was identified. This PTCH gene is
located within the TCC1 region. However, no mutations in this
gene in bladder tumours were observed (Simoneau et al, 1996; our
unpublished results). For oesophagus carcinoma, the region
containing a putative TSG has been narrowed down to about
200 kb, between the markers D9S155 and D9S177. These
microsatellites are positioned distal of the TCC1 region and prox-
imal to the DBC1 region. In ovarian cancer, LOH is found around
the gelsolin gene (GSN), where the DBC1 gene is expected.
Both the TCC1 and TCC2 regions were screened for the pres-
ence of homozygous deletion in 17 bladder tumour cell lines with
in total 100 microsatellite markers, with an average spacing of
300–500 kb. Deletions of the CDKN2 region are often between 50
and 500 kb or more in size (Williamson et al, 1995). Other homozy-
gous deletions vary between 130 kb in B-cell chronic lymphocytic
leukaemia (Corcoran et al, 1998), and 3 Mb in non-small cell lung
cancer (Kohno et al, 1998). This suggests that the homozygous
deletion targeting the TCC1 and TCC2 loci are either much smaller
in size than those observed for other loci or that the putative TSGs
are not readily inactivated by homozygous deletions.
Several interesting genes in the TCC2 region are known: the trans-
forming growth factor b receptor type I gene (TGFBR1), the death
associated protein kinase 1 gene (DAPK1) and the tuberous sclerosis
1 gene (TSC1). Further studies to identify the genes involved in
bladder cancer should include these genes as candidates.
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